Table 1.

Patient demographics and pretreatment characteristics

CharacteristicNo.%
Median age, y (range) 60 (47-75)  
Sex, male/female 20/10 67/33 
Karnofsky index   
 Less than 80% 20 
 Between 80% and 100% 24 80  
Median time since first CLL diagnosis, y (range) 5 (1-19)  
Histological type   
 B-CLL 29 97 
 B-PLL 3  
Binet stage at study entry   
 B 11 37  
 C 19 63  
B symptoms 14 47  
Bone marrow infiltration (n = 28)   
 Nodular 13 46  
 Mixed 21 
 Diffuse 32  
No. of previous treatments for CLL   
 1 3  
 2 17  
 3 27 
 4 13  
 More than 4 12 40  
Time since end of last CLL treatment   
 No more than 12 wk 10 33 
 3-6 mo 20  
 6-12 mo 27  
 1-2 y 10 
 More than 2 y 10 
CharacteristicNo.%
Median age, y (range) 60 (47-75)  
Sex, male/female 20/10 67/33 
Karnofsky index   
 Less than 80% 20 
 Between 80% and 100% 24 80  
Median time since first CLL diagnosis, y (range) 5 (1-19)  
Histological type   
 B-CLL 29 97 
 B-PLL 3  
Binet stage at study entry   
 B 11 37  
 C 19 63  
B symptoms 14 47  
Bone marrow infiltration (n = 28)   
 Nodular 13 46  
 Mixed 21 
 Diffuse 32  
No. of previous treatments for CLL   
 1 3  
 2 17  
 3 27 
 4 13  
 More than 4 12 40  
Time since end of last CLL treatment   
 No more than 12 wk 10 33 
 3-6 mo 20  
 6-12 mo 27  
 1-2 y 10 
 More than 2 y 10 

PLL indicates prolymphocytic leukemia.

Close Modal

or Create an Account

Close Modal
Close Modal